Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...
Celltrion’s senior executives attended the conference to present the company’s latest progress in new drug development and ...
The American Cancer Society reports that five-year cancer survival in the US has reached a historic high of 70% for the first ...
The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...
InvestorsHub on MSN
ImmunityBio shares jump after Saudi approval of ANKTIVA for lung cancer
Shares of ImmunityBio (NASDAQ:IBRX) climbed 6% on Wednesday morning after the company said Saudi Arabia’s Food and Drug ...
The FDA has issued a second complete response letter to Atara Biotherapeutics for its biologicals license application of ...
Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...
The anti-tumor immune response involves a series of complex steps mediated by various immune cells and signaling molecules.
Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these ...
TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...
Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these ...
Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback